Table 2 Baseline characteristics of the study patients after the 1:1 propensity score analysis
|  | Non-antiviral group, n = 100 | Antiviral group, n = 100 | p value |
|---|---|---|---|
Age, years | 56 (50–65) | 59 (50–65) | 0.539 |
Male sex, n (%) | 83 (83) | 83 (83) | > 0.999 |
ALT, IU/m | 33.5 (24.0-46.8) | 35 (27–56) | 0.258 |
AST, IU/ml | 34 (28–52) | 39.0 (29.2–57.8) | 0.382 |
ALP, IU/L | 90.5 (75.0-129.8) | 96.5 (73.2–128.8) | 0.59 |
ALB, g/L | 40.5 (37.0-43.2) | 40.6 (37.0–43.0) | 0.931 |
Total bilirubin, mg/dl | 16.9 (14.2–22.4) | 18.3 (12.9–24.1) | 0.851 |
PT, s | 11.7 (10.8–12.5) | 11.4 (11.0–12.2) | 0.479 |
AFP, ng/ml | 11.9 (3.2-357.9) | 34.5 (18.0–828.2) | 0.002 |
PLT, 109/L | 96 (88–199) | 97 (91–198.8) | 0.287 |
Satellite nodules, n (%) | 15 (15) | 15 (15) | > 0.999 |
Capsular, n (%) | 21 (21) | 17 (17) | 0.471 |
Moderate/poor tumor differentiation, n (%) | 35 (35) | 36 (36) | 0.883 |
Vascular invasion, n (%) | 19 (19) | 13 (13) | 0.247 |
Tumor size, cm | 5.5 (3–7) | 5 (3–8) | 0.94 |
Multiple tumor, n (%) | 15 (15) | 9 (9) | 0.342 |
Cirrhosis, n (%) | 66 (66) | 65 (65) | 0.882 |
Hypertension, n (%) | 26 (26) | 29 (29) | 0.635 |
Diabetes mellitus, n (%) | 17 (17) | 21 (21) | 0.471 |
History of smoking, n (%) | 38 (38) | 40 (40) | 0.772 |
History of drinking, n (%) | 35 (35) | 34 (34) | 0.882 |
HBeAg positive, n (%) | 17 (17) | 18 (18) | 0.852 |
Child–Pugh score |  |  | 0.316 |
 A | 100 | 99 |  |
 B | 0 | 1 |  |
BCLC stage | Â | Â | 0.693 |
 Very early (0) | 8 | 10 |  |
 Early (A) | 35 | 37 |  |
 Intermediate (B) | 38 | 40 |  |
 Advanced (C) | 19 | 13 |  |